-
News Agency News Aggregator Journalist/Editor Broking House Others
AMRUTANJAN - Closure of Trading Window
AMRUTANJAN - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
#BeatTheStreet | Divis Labs' share price has been disappointing, while several whistle-blower complaints have been registered against Amrutanjan So, why is Saurabh Mukherjea of @MarcellusInvest still holding these stocks? Watch to find out- @AyeshaFaridi1 @_anishaj
#BeatTheStreet | "We have doubled position in Divi's Labs in the last 12 months. Amrutanjan has very high cash conversion with no debts," says Saurabh Mukherjea of @MarcellusInvest #StockMarket #StocksToWatch #Nifty
AMRUTANJAN - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
#Amrutanjan 5 दिन में 10% टूटकर 52 हफ्ते के निचले स्तर पर अमृतांजन के शेयरों में क्यों आई गिरावट? जानिए डिटेल्स आशीष चतुर्वेदी से .... देखिए Zee Business LIVE - @AshishZBiz
#Amrutanjan shares fall 8% on whistleblower allegations
Amrutanjan dives 10% on allegations
Amrutanjan Shares Fall 10% On Whistleblower Allegations
705 to 650 already Amrutanjan.. In current times, market surely not going to take whistleblower allegations kindly, it didn't take it kindly even for companies like Infosys in the past.
While I can’t comment for want of facts, Amrutanjan rest release highlights a whistle blower complaint alleging lapses by sr mgt. investigation on. Mgt says cannot quantify impact till concluded. Point 4 of notes.
Amrutanjan 52 w low. One by one. Buy at any price is turning sorry from story
#EarningsWithETNOW | Amrutanjan Health Q3FY23 -Cons PAT at Rs 11 cr vs Rs 21 cr, down 48% YoY -Cons revenue at Rs 98 cr vs Rs 111 cr; down 11.8% YoY @AmrutanjanH #StocksToWatch #StockMarket
AMRUTANJAN HEALTH CARE: Q3 SL NET PROFIT 107M RUPEES VS 206M (YOY); 128M (QOQ) || Q3 REVENUE 976M RUPEES VS 1.1B (YOY); 1.1B (QOQ)
AMRUTANJAN - Board Meeting Outcome for Outcome Of The Board Meeting
Marcellus owns Amrutanjan in their portfolio?
If anyone has Amrutanjan Healthcare in portfolio, prudent to exit at cmp.
-